Which Came First? Alogliptin Avoids Possible Exclusivity Dispute
This article was originally published in RPM Report
Executive Summary
An unusual footnote in FDA’s approval letter for Takeda’s long-delayed diabetes medicine means that the company won’t have to worry about losing five-year exclusivity on the molecule.